Therapeutic and diagnostic implications of Hsp90 activation

Trends in Molecular Medicine

Volumn 10, Issue 6, 2004, Pages 283-290

  Kamal, Adeela ^a   Boehm, Marcus F ^a   Burrows, Francis J ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 AMINOGELDANAMYCIN; ANTINEOPLASTIC AGENT; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CRYSTAL STRUCTURE; DRUG SELECTIVITY; HUMAN; MOLECULAR MECHANICS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; VIRUS INFECTION;

ANIMALS; BENZOQUINONES; CLINICAL TRIALS; ENZYME ACTIVATION; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RIFABUTIN; SIGNAL TRANSDUCTION;

EID: 2642521990     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.04.006     Document Type: Review

References (70)

1. Isaacs J.S., et al. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 3:2003;213-217
2. Pratt W.B., Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood). 228:2003;111-133
3. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42:1998;273-279
4. Xu W., et al. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J. Biol. Chem. 276:2001;3702-3708
5. Basso A.D., et al. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 21:2002;1159-1166
6. Schulte T.W., et al. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem. 270:1995;24585-24588
7. An W.G., et al. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 11:2000;355-360
8. Blagosklonny M.V., et al. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene. 11:1995;933-939
9. + lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res. 62:2002;1559-1566
10. Yao Q., et al. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin. Cancer Res. 9:2003;4483-4493
11. Fumo G., et al. 17-allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood. 103:2004;1078-1084
12. Solit D.B., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 8:2002;986-993
13. Whitesell L., Cook P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol. Endocrinol. 10:1996;705-712
14. Smith D.F., et al. Reconstitution of progesterone receptor with heat shock proteins. Mol. Endocrinol. 4:1990;1704-1711
15. Kosano H., et al. The assembly of progesterone receptor-hsp90 complexes using purified proteins. J. Biol. Chem. 273:1998;32973-32979
16. Whitesell L., et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8324-8328
17. Prodromou C., et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 90:1997;65-75
18. Stebbins C.E., et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell. 89:1997;239-250
19. Obermann W.M., et al. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J. Cell Biol. 143:1998;901-910
20. Panaretou B., et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 17:1998;4829-4836
21. Grenert J.P., et al. The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. J. Biol. Chem. 274:1999;17525-17533
22. Miller P., et al. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res. 54:1994;2724-2730
23. Mimnaugh E.G., et al. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271:1996;22796-22801
24. Supko J.G., et al. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36:1995;305-315
25. Solit D.B., et al. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 63:2003;2139-2144
26. Sausville E.A., et al. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets. 3:2003;377-383
27. Chiosis G., et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8:2001;289-299
28. Kamal A., et al. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature. 425:2003;407-410
29. Stepanova L., et al. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10:1996;1491-1502
30. Datta S.R., et al. Cellular survival: a play in three Akts. Genes Dev. 13:1999;2905-2927
31. Blagosklonny M.V., et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 15:2001;1537-1543
32. Nimmanapalli R., et al. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 61:2001;1799-1804
33. Gorre M.E., et al. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100:2002;3041-3044
34. Smith V., et al. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res. 22:2002;1993-1999
35. Xu L., et al. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J. Pharmacokinet. Pharmacodyn. 30:2003;185-219
36. Ferrarini M., et al. Unusual expression and localization of heat-shock proteins in human tumor cells. Int. J. Cancer. 51:1992;613-619
37. Gress T.M., et al. Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Res. 54:1994;547-551
38. Yano M., et al. Expression and roles of heat shock proteins in human breast cancer. Jpn. J. Cancer Res. 87:1996;908-915
39. Mileo A.M., et al. Selective over-expression of mRNA coding for 90 KDa stress-protein in human ovarian cancer. Anticancer Res. 10:1990;903-906
40. Cardillo M.R., et al. Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res. 20:2000;4579-4583
41. Zou J., et al. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 94:1998;471-480
42. Morimoto R.I. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev. 12:1998;3788-3796
43. Bagatell R., et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin. Cancer Res. 6:2000;3312-3318
44. Roe S.M., et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42:1999;260-266
45. Chene P. ATPases as drug targets: learning from their structure. Nat. Rev. Drug Discov. 1:2002;665-673
46. Chiosis G., et al. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10:2002;3555-3564
47. Dymock B., et al. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 14:2004;325-328
48. Neckers L., Lee Y.S. Cancer: the rules of attraction. Nature. 425:2003;357-359
49. Jez J.M., et al. Crystal Structure and Molecular Modeling of 17-DMAG in Complex with Human Hsp90. Chem. Biol. 10:2003;361-368
50. Prodromou C., et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)- domain co-chaperones. EMBO J. 18:1999;754-762
51. McLaughlin S.H., et al. Stimulation of the weak ATPase activity of human hsp90 by a client protein. J. Mol. Biol. 315:2002;787-798
52. Roe S.M., et al. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell. 116:2004;87-98
53. Panaretou B., et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol. Cell. 10:2002;1307-1318
54. Meyer P., et al. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol. Cell. 11:2003;647-658
55. Hatanaka Y., et al. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest™ in breast carcinoma by image analysis. Pathol. Int. 51:2001;33-36
56. Vogen S., et al. Radicicol-sensitive peptide binding to the N-terminal portion of GRP94. J. Biol. Chem. 277:2002;40742-40750
57. Conde A.G., et al. Induction of heat shock proteins by tyrosine kinase inhibitors in rat cardiomyocytes and myogenic cells confers protection against simulated ischemia. J. Mol. Cell. Cardiol. 29:1997;1927-1938
58. Xiao N., et al. Geldanamycin provides posttreatment protection against glutamate- induced oxidative toxicity in a mouse hippocampal cell line. J. Neurochem. 72:1999;95-101
59. Lu A., et al. Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J. Neurochem. 81:2002;355-364
60. Hu J., Seeger C. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 93:1996;1060-1064
61. Waxman L., et al. Host cell factor requirement for hepatitis C virus enzyme maturation. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13931-13935
62. Li Y.H., et al. Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro. Antimicrob. Agents Chemother. 48:2004;867-872
63. O'Keeffe B., et al. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J. Biol. Chem. 275:2000;279-287
64. Yorgin P.D., et al. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases. J. Immunol. 164:2000;2915-2923
65. Sugita T., et al. Immunosuppressive effects of the heat shock protein 90-binding antibiotic geldanamycin. Biochem. Mol. Biol. Int. 47:1999;587-595
66. Piatelli M.J., et al. Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes. J. Biol. Chem. 277:2002;12144-12150
67. Beere H.M., Green D.R. Stress management - heat shock protein-70 and the regulation of apoptosis. Trends Cell Biol. 11:2001;6-10
68. Sittler A., et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10:2001;1307-1315
69. Auluck P.K., Bonini N.M. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8:2002;1185-1186
70. Rutherford S.L., Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature. 396:1998;336-342